Navigation Links
ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
Date:3/2/2010

s will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
2. Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
3. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
4. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
5. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
6. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
9. ViroPharma Announces Discontinuation of HCV-796 Development
10. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
11. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.Y. , July 24, 2014  Kinex Pharmaceuticals ... FDA for the Company,s KX2-391 Ointment for the commencement ... This is the Company,s third IND to be allowed ... KX2-391 is a synthetic, orally active and ... tubulin polymerization. KX2-391 promotes the induction of p53, G2/M ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... Tank" – a forum designed to give pediatric health ... product solution to a panel of acclaimed judges for ... the innovation and bring it to market. ... will be moderated by Daymond John of ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... MOUNTAIN VIEW, Calif., Nov. 7, 2011 Alexza Pharmaceuticals, ... results for the fiscal quarter ended September 30, 2011 ... the quarters ended September 30, 2011 and 2010, as ... the United States (GAAP), were $13.4 million and $0.6 ...
... LIBERTY, Mo. and DANBURY, Conn., Nov. 7, 2011 ... "Planet"), a privately held specialty pharmaceutical company focused on ... that it had completed an asset sale of ALLERGY ... ACQUISITION LLC, a New Jersey limited liability company. ...
Cached Medicine Technology:Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 2Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 3Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 4Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 5Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 6Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 7
(Date:7/24/2014)... ultrasounds uncover antenatal hydronephrosis, or enlarged kidneys, the ... States. Many children with this abnormality are treated ... years of life with the hopes of preventing ... however, little evidence existed as to the benefits ... inconvenience for families. But a study published this ...
(Date:7/24/2014)... American air and missile defense radar market is estimated to ... a CAGR of 8.22% to reach $2.7 billion in 2020. ... and missile defense radar system. However, in the recent economic ... , Browse through the TOC of the North American air ... of the in-depth analysis provided. This report also provides a ...
(Date:7/24/2014)... composed of a single soul inhabiting two bodies." Poetic ... were made in heaven for each other can hurt ... observe that people talk and think about love in ... common themes that frame how we think about relationships. ... unity ("made for each other," "she,s my other half"); ...
(Date:7/24/2014)... 24, 2014 The National Resident ... launch of a new version of its smartphone app, ... PRISM, for applicants participating in NRMP’s Main Residency Match® ... track and organize program information during the interview process ... creating their rank order lists. Rank order lists ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 RxNetwork ... of prescription non-adherence at Cardinal Health RBC 2014 ... Utilizing familiar and user-friendly Mobile devices, RxNetwork is ... payers. , Already embraced by over 100 ... patients and caregivers through timely alerts and messages ...
Breaking Medicine News(10 mins):Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 2Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:New research: When it hurts to think we were made for each other 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3Health News:RxNetwork Brings the Next Generation Customer Care Connectivity to Pharmacies, Providers, and Patients 2
... have identified two genes believed to play a role in ... to better diagnosis and treatment of this increasingly common form ... or womb cancer, is the most common malignant cancer of ... of cases being detected has increased markedly, as has mortality. ...
... While studying an HIV protein that plays an essential ... Pittsburgh School of Medicine have discovered compounds that show ... drug discovery efforts have met with little success in ... factor, called Nef, because it lacks biochemical activity that ...
... how your eyes adjust during a blackout? When we go ... must quickly adjust. Vision scientists at Washington University School of ... allows the human eye to adapt to darkness very quickly. ... bright light. The discovery could contribute to better understanding ...
... treatments instead, study finds, , TUESDAY, Oct. 13 (HealthDay News) ... cancer are not turning to mastectomy as their first choice ... as lumpectomy, a new survey has found. , The survey, ... of the American Medical Association , also found that U.S. ...
... ... Support for the Nationwide Health Information Network. , ... Chantilly, VA (PRWEB) October 13, 2009 -- Agilex Technologies, Inc. , ... and public sectors , today announced the appointment of Melissa Chapman to the ...
... fastest-growing retailer of authentic nonfat frozen yogurt, announced it ... , to celebrate the favorite food of the fall ... Spice frozen yogurt, available at all Red Mango ... 13, through December 31, 2009. , (Photo: ...
Cached Medicine News:Health News:Genes behind increasingly common form of cancer identified 2Health News:Pitt researchers find candidates for new HIV drugs 2Health News:Researchers discover mechanism that helps humans see in bright and low light 2Health News:Researchers discover mechanism that helps humans see in bright and low light 3Health News:Mastectomy Not First Choice for Most Breast Cancer Patients 2Health News:Mastectomy Not First Choice for Most Breast Cancer Patients 3Health News:Agilex Technologies Hires Former HHS CIO Melissa Chapman to Lead Health Technology Programs 2Health News:Agilex Technologies Hires Former HHS CIO Melissa Chapman to Lead Health Technology Programs 3Health News:Discover Red Mango's New Seasonal Flavor: Pumpkin Spice 2
... heavy duty, controlled stretch knee support that ... allowing full range of motion. The ... the knee, and help to keep the ... This is an excellent support for ...
... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
... Scoring: , One of the outstanding features ... our patented Three-Dimensional Molding Technology. , This ... brace which effectively controls the bunching and ... comfort to the wearer. , ...
... new padding system from Innovation Sports. Exceptionally ... contours to the unique anatomy of each ... Gel Fit's proprietary Octogrip™ Anti-Slip System improves ... when the brace is strapped on. Gel ...
Medicine Products: